(VIANEWS) – Essent Group Ltd. (ESNT), Stifel Financial Corporation (SF), Surgery Partners (SGRY) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Essent Group Ltd. (ESNT)
17.7% sales growth and 14.56% return on equity
Essent Group Ltd., through its subsidiaries, provides private mortgage insurance and reinsurance for mortgages secured by residential properties located in the United States. Its mortgage insurance products include primary, pool, and master policy. The company also provides information technology maintenance and development services; customer support-related services; underwriting consulting; and contract underwriting services. It serves the originators of residential mortgage loans, such as regulated depository institutions, mortgage banks, credit unions, and other lenders. The company was founded in 2008 and is based in Hamilton, Bermuda.
Earnings Per Share
As for profitability, Essent Group Ltd. has a trailing twelve months EPS of $6.5.
PE Ratio
Essent Group Ltd. has a trailing twelve months price to earnings ratio of 8.22. Meaning, the purchaser of the share is investing $8.22 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.56%.
Yearly Top and Bottom Value
Essent Group Ltd.’s stock is valued at $53.46 at 01:22 EST, way below its 52-week high of $59.90 and way above its 52-week low of $40.33.
Revenue Growth
Year-on-year quarterly revenue growth grew by 24.2%, now sitting on 1.09B for the twelve trailing months.
2. Stifel Financial Corporation (SF)
11.7% sales growth and 9.84% return on equity
Stifel Financial Corp., a financial services and bank holding company, provides retail and institutional wealth management, and investment banking services to individual investors, corporations, municipalities, and institutions in the United States, the United Kingdom, the rest of Europe, and Canada. It operates in three segments: Global Wealth Management, Institutional Group, and Other. The company provides private client services, including securities transaction and financial planning services; institutional equity and fixed income sales, trading and research, and municipal finance services; investment banking services, such as mergers and acquisitions, public offerings, and private placements; and retail and commercial banking services comprising personal and commercial lending programs, as well as deposit accounts. It also participates in and manages underwritings for corporate and public finance; and offers financial advisory and securities brokerage services. The company was founded in 1890 and is headquartered in St. Louis, Missouri.
Earnings Per Share
As for profitability, Stifel Financial Corporation has a trailing twelve months EPS of $4.28.
PE Ratio
Stifel Financial Corporation has a trailing twelve months price to earnings ratio of 17.99. Meaning, the purchaser of the share is investing $17.99 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.84%.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Feb 29, 2024, the estimated forward annual dividend rate is 1.68 and the estimated forward annual dividend yield is 2.18%.
Volume
Today’s last reported volume for Stifel Financial Corporation is 313630 which is 42.17% below its average volume of 542422.
3. Surgery Partners (SGRY)
9.2% sales growth and 4.07% return on equity
Surgery Partners, Inc., through its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company operates through two segments, Surgical Facility Services and Ancillary Services. Its surgical facilities comprise ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including gastroenterology, general surgery, ophthalmology, orthopedics, and pain management. The company's surgical hospitals also provide ancillary services, such as diagnostic imaging, pharmacy, laboratory, obstetrics, oncology, physical therapy, and wound care; and ancillary services, which consist of multi-specialty physician practices, urgent care facilities, and anesthesia services. As of December 31, 2021, it owned or operated a portfolio of 126 surgical facilities, including 108 ambulatory surgical centers and 18 surgical hospitals in 31 states. Surgery Partners, Inc. was founded in 2004 and is headquartered in Brentwood, Tennessee.
Earnings Per Share
As for profitability, Surgery Partners has a trailing twelve months EPS of $-0.09.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.07%.
Sales Growth
Surgery Partners’s sales growth is 4.7% for the present quarter and 9.2% for the next.
Yearly Top and Bottom Value
Surgery Partners’s stock is valued at $23.83 at 01:22 EST, way below its 52-week high of $45.79 and above its 52-week low of $22.05.
Volume
Today’s last reported volume for Surgery Partners is 1582150 which is 76% above its average volume of 898938.
4. WD-40 Company (WDFC)
8.2% sales growth and 33.12% return on equity
WD-40 Company develops and sells maintenance products, and homecare and cleaning products in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company offers multi-purpose maintenance products, including aerosol sprays, non-aerosol trigger sprays, and in liquid-bulk form products under the WD-40 Multi-Use brand name for various consumer uses and industrial applications; and specialty maintenance products, such as penetrants, degreasers, corrosion inhibitors, greases, lubricants, and rust removers under the WD-40 Specialist brand, as well as various products under the WD-40 Bike brand name. It also provides multi-purpose and specialty drip oils, and spray lubricant products, as well as other specialty maintenance products under the 3-IN-ONE brand name; and professional spray maintenance products and lubricants for the bike market under the GT85 brand name. In addition, the company offers automatic toilet bowl cleaners under the 2000 Flushes brand name; aerosol and liquid trigger carpet stain and odor eliminators under the Spot Shot brand; room and rug deodorizers under the Carpet Fresh brand name; carpet and household cleaners, and rug and room deodorizers under the 1001 brand; heavy-duty hand cleaner products under the Lava brand name in the United States, as well as under the Solvol brand name in Australia; and liquid mildew stain removers and automatic toilet bowl cleaners under the X-14 brand name. It sells its products primarily through warehouse club stores, hardware stores, automotive parts outlets, industrial distributors and suppliers, mass retail and home center stores, value retailers, grocery stores, online retailers, farm supply, sport retailers, and independent bike dealers. WD-40 Company was founded in 1953 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, WD-40 Company has a trailing twelve months EPS of $5.03.
PE Ratio
WD-40 Company has a trailing twelve months price to earnings ratio of 46.98. Meaning, the purchaser of the share is investing $46.98 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 33.12%.
Volume
Today’s last reported volume for WD-40 Company is 132313 which is 10.66% above its average volume of 119564.
5. PriceSmart (PSMT)
7.4% sales growth and 11.44% return on equity
PriceSmart, Inc. owns and operates U.S. style membership shopping warehouse clubs in the United States, Central America, the Caribbean, and Colombia. Its warehouse clubs sell brand name and private label consumer products, essential goods, fresh produce, prepared foods, and fresh-baked goods, as well as provides services, such as optical, tire center, and other ancillary services. The company also operates Click & Go, an e-commerce platform for online ordering, curbside pickup, and delivery services. As of March 29, 2022, it operated 49 warehouse clubs in 12 countries and one U.S. territory. PriceSmart, Inc. was incorporated in 1994 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, PriceSmart has a trailing twelve months EPS of $3.97.
PE Ratio
PriceSmart has a trailing twelve months price to earnings ratio of 20.01. Meaning, the purchaser of the share is investing $20.01 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.44%.
Yearly Top and Bottom Value
PriceSmart’s stock is valued at $79.45 at 01:22 EST, under its 52-week high of $86.90 and way higher than its 52-week low of $61.82.
Moving Average
PriceSmart’s worth is under its 50-day moving average of $81.39 and higher than its 200-day moving average of $76.09.
Volume
Today’s last reported volume for PriceSmart is 167403 which is 13.38% above its average volume of 147637.
6. Consolidated Edison (ED)
7% sales growth and 11.97% return on equity
Consolidated Edison, Inc., through its subsidiaries, engages in the regulated electric, gas, and steam delivery businesses in the United States. It offers electric services to approximately 3.7 million customers in New York City and Westchester County; gas to approximately 1.1 million customers in Manhattan, the Bronx, parts of Queens, and Westchester County; and steam to approximately 1,530 customers in parts of Manhattan. The company also supplies electricity to approximately 0.3 million customers in southeastern New York and northern New Jersey; and gas to approximately 0.2 million customers in southeastern New York. In addition, it operates 545 circuit miles of transmission lines; 15 transmission substations; 63 distribution substations; 90,051 in-service line transformers; 3,788 pole miles of overhead distribution lines; and 2,314 miles of underground distribution lines, as well as 4,363 miles of mains and 380,870 service lines for natural gas distribution. Further, the company invests in electric and gas transmission projects. It primarily sells electricity to industrial, commercial, residential, and government customers. Consolidated Edison, Inc. was founded in 1823 and is based in New York, New York.
Earnings Per Share
As for profitability, Consolidated Edison has a trailing twelve months EPS of $7.21.
PE Ratio
Consolidated Edison has a trailing twelve months price to earnings ratio of 12.29. Meaning, the purchaser of the share is investing $12.29 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.97%.
Yearly Top and Bottom Value
Consolidated Edison’s stock is valued at $88.63 at 01:22 EST, way below its 52-week high of $100.92 and way above its 52-week low of $80.46.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Consolidated Edison’s EBITDA is 3.75.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Feb 13, 2024, the estimated forward annual dividend rate is 3.32 and the estimated forward annual dividend yield is 3.68%.
7. Vertex Pharmaceuticals (VRTX)
6.1% sales growth and 22.99% return on equity
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Earnings Per Share
As for profitability, Vertex Pharmaceuticals has a trailing twelve months EPS of $13.89.
PE Ratio
Vertex Pharmaceuticals has a trailing twelve months price to earnings ratio of 28.55. Meaning, the purchaser of the share is investing $28.55 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 22.99%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 32.5% and 5.9%, respectively.
Sales Growth
Vertex Pharmaceuticals’s sales growth is 10.2% for the current quarter and 6.1% for the next.
